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Introduction:
Epistaxis is one of common referral seen by Otolaryngologist. Survey data suggested that about 60% 1 of adult have experienced an episode of epistaxis in their lifetime. Most epistaxis resolved spontaneously. About 6% have sought medical attention. There is subset of patient with intractable epistaxis that fail conservative treatment and most commonly occur in the posterior part of nasal airway. . The differential diagnosis include hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease), blood dyscrasia and secondary to severe asymptomatic hypertension. In this case study, we are proposing that there is an association between vaping and epistaxis.
Case report:
A 26 years old male, with no known underlying illness has been referred to our attention by the casualty doctor for bilateral epistaxis. The epistaxis, about one small towel fully soaked, started suddenly in the evening and stopped spontaneously. He had another episode of epistaxis the next morning after waking up from bed, which also stopped spontaneously. Later, he had another episode of epistaxis that did not stop spontaneously at home, therefore prompting him to seek further treatment at the emergency department.
He denied history of trauma or any recent upper respiratory tract infection. He has no symptoms of allergic rhinitis and also no previous history of epistaxis. Patient admitted to use to smoke about 10 cigarettes per day but since stopped smoking and replacing it with vaping which he started about 1 month ago. Within that period of 1 month, he vape regularly and had tried variety of different flavoured type.
On examination, the left nostril was seen bleeding actively while the right nostril oozed blood. There were no obvious polyps or mass seen in the nose. Blood pressure was documented at 140/80 mmHg with pulse of 82bpm and temperature of 37 degree Celcius. Both nostrils were packed with merocel size 10mm and the patient was admitted to the ward for observation.
In the ward, intravenous Augmentin was started and regular bolster charting was done.The epistaxis persisted after nasal pack was removed 48 hours later which during the time there were no evidence of bleeding evidence by the bolster chart. In view of the persistence epistaxis, he was scheduled for examination under general anaesthesia for proper assessment to find the cause of bleeding.
Intraoperatively, generalised 'spider nevi' appearances on the mucosal surfaces seen especially over medial surface of the inferior turbinate, anterior surface of middle turbinate and septum in both nostrils. The 'spider nevi', telangiectasia like vessel easily bled and looked very fragile. Each involved area were diathermised using bipolar bilaterally at best to addressed the more prominent of the 'spider nevi' lesion. Nasopore nasal packs were inserted in both nostrils right after chloramphenicol ointment was applied over bilateral nasal cavity.
Fig.-1: Endoscopic image of the right nostril
Postoperatively, no epistaxis documented.A week follow up, patientdid not complain of any episode of epistaxis and the endoscopic examination shows crusting over the diathermised area with no evidence of bleeding. The histopathology result from the affected area came back with no significant pathology. After 6 months follow up, patient had no episode of epistaxis and he climed that he has stopped vapping and smoking.
Discussion:
Epistaxis is a common presentation that requires Otorhinolaryngology referral, affecting about 60 percent of the population, 1 which can lead to hospital admission and seldom require surgical intervention. It is estimated about 6% in minority of patient that the bleeding continues and requires medical attention.For most patients, epistaxis resolved spontaneously particularly in the anterior epistaxis. Local pressure or nasal packing is sufficient for most patients. 2 One of the common causes of epistaxis is the spontaneous idiopathic atraumatic epistaxis. It has a bimodal age distribution with cases before age 10 and between 45 and 65 years old. 3 4 Hospital admission increases progressively with age.
Patients who fail conservative measures are said to have intractable epistaxis. This is common in patient with posterior epistaxis as it can be difficult to manage and require more intensive level of care 2 .Arteriosclerosis and hypertension are most common risk factors for epistaxis in older patients with posterior bleeds. However, in this case patient has no known medical illness and his intractable epistaxis occured at the anterior part of the nasal airway.
Other spectrums of differential diagnosis in epistaxis can be from local factors, systemic disorders, environmental factors, benign to malignant neoplasm and genetic disorder. Examples include trauma, foreign body, cold and dry air, carcinomas as well as Osler-Weber-Rendu disease. In tropical country, epistaxis is a known complication of thrombocytopenia due to dengue fever.Therefore, it is crucial to identify the causes of epistaxis in order to manage the condition appropriately.
One of the direct treatment of visibly localised traumatic epistaxis over the anterior part of the nasal airway is having to stopped the bleeding area under direct vision. This can be achieved by cauterizing it using silver nitrate or electrocautery. About 90 to 95 percent anterior epistaxis stopped with nasal packing. 5, 6 While on nasal packing, it is alsoadvisable to start prophylactic antibiotics especially those with diabetes, advanced age or immunosuppressed. An antibiotics with staphylococcal coverage such as amoxicillin-clavulanate or second generation cephalosporin was recommended. 7 In the event of intractable epistaxis after conservative measures and nasal packing, surgical treatment is performed. Thesemay include ligation of the sphenopalatine or anterior ethmoidal artery. Angiographic embolization is becoming more common and the result is about 90 percent successful rate. 8, 9 However, there are 4percent rate of severe complications like stroke and blindness with embolization. 10 In this case study, we were unable to detect any obvious causes that may lead this patient to have an anterior nasal airway spontaneous intractable epistaxis episodes besides his prior engagement in vaping habit. There is not yet case study published reporting the association between vaping habit and intractable epistaxis.
Vape or electronic cigarette contains propylene glycol or glycerol also called propane-1,2-diol, is an organic compound with the chemical formula C 3 H 8 O 2 as one of the major ingredient apart from liquid nicotine and flavouring used in the electronic cigarettes. Very little is known to human about the effect of heated and aerosolized propylene glycol. It can decomposes and form propylene oxide, a probable human carcinogen at high temperature. 11 Both propylene glycol and glycerol decompose to form carcinogens formaldehyde and acetaldehyde depending on the voltage of the battery used in the e-cigarette. 12, 13 An e-cigarette consists of a catridgec ontining a liquid, an atomizer which is a vaporization chamber with a heating element and a battery. Activation of the atomizer will heat the liquid and produces a vapor to inhale. Also in e-cigarette, a significant number of the flavour chemicals used were aldehydes, a compound class recognised as 'primary irritants' of mucosal tissue of the respiratory tract. 14 The possible correlation and explaination to what may causes epistaxis when vaping in our case is that the combination of drying effect of the vapour and its irritative chemicals causes the epistaxis. Further evidence and research is much needed. Further questions can also be raised in finding out the longterm consequences of e-cigarette use which is still unknown.
Conclusion:
This is the first case study trying to associate between habit and intractable epistaxis. Intractable anterior epistaxis was observed without any other remarkable history apart from significant history of recent vaping habit. More data and study needed for the evaluation of the association between vaping or e cigarette with epistaxis.
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